RT Journal Article SR Electronic T1 Biologic Therapies for Psoriasis JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 62 OP 64 DO 10.3899/jrheum.090228 VO 83 A1 CATIA de FELICE A1 MARCO ARDIGO A1 ENZO BERARDESCA YR 2009 UL http://www.jrheum.org/content/83/62.abstract AB Psoriasis is a common chronic inflammatory skin disease that may lead to disability and significant effects on patients’ quality of life. A challenge in psoriasis management is to use an effective therapy early in the disease course in order to achieve a safe and well tolerated maintenance of remission with an improvement of both skin and joint manifestations. Recent advances in knowledge of the pathogenesis of psoriasis helped develop targeted treatment options that may be effective and well tolerated over long periods of administration, thus improving the patient’s quality of life. These novel “biologic” agents specifically target tumor necrosis factor–α (infliximab, etanercept, and adalimumab) or T cells (efalizumab).